65 % of eligible lung cancer patients do not receive the most appropriate targeted therapies, Diaceutics report finds
Diaceutics, the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, has released new research revealing a critical shift in precision medicine. Despite